文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

Delta与Omicron变异株时代重症COVID-19相关肺曲霉病的前瞻性多中心研究

COVID-19 associated pulmonary aspergillosis in critically-ill patients: a prospective multicenter study in the era of Delta and Omicron variants.
PubMed 文献 · Ann Intensive Care · 2024-04-24
一句话结论Delta与Omicron时代重症COVID-19患者CAPA总患病率5.1%,有创机械通气者升至9.1%,CAPA患者机械通气与ICU住院时间显著延长,但28天死亡率无显著差异。

该前瞻性多中心观察性队列研究于2021年12月7日至2023年4月26日在法国36个ICU开展,纳入566例重症COVID-19患者,CAPA诊断依据ECMM/ISHAM共识标准。CAPA总患病率为5.1%[95%CI 3.4-7.3],需要IMV的患者中升至9.1%。多因素logistic回归显示,ICU入科时SAPS II评分、免疫抑制和SARS-CoV-2 Delta变异株与CAPA独立相关。CAPA与28天死亡率无显著关联,但CAPA患者机械通气时间和ICU住院时间更长。

要点

  • 重症COVID-19患者CAPA总患病率为5.1%[95%CI 3.4-7.3],需要IMV者升至9.1%。
  • CAPA患者更常见免疫抑制,ICU期间更常需要IMV、血管升压药和肾脏替代治疗。
  • 多因素分析中,ICU入科SAPS II评分、免疫抑制和SARS-CoV-2 Delta变异株与CAPA独立相关。
  • CAPA与28天死亡率无显著关联,但CAPA患者机械通气时间和ICU住院时间显著更长。

适用人群与场景

  • 2021年12月7日至2023年4月26日在法国36个ICU收治的重症COVID-19患者,共纳入566例。

诊断标准与关键阈值

  • CAPA诊断依据欧洲医学真菌学联合会(ECMM)/国际人类与动物真菌学会(ISHAM)共识标准。

研究设计与关键结果

  • 研究类型为前瞻性多中心观察性队列研究,在法国36个ICU开展,纳入566例重症COVID-19患者。
  • CAPA总患病率为5.1%[95%CI 3.4-7.3],需要IMV的患者中为9.1%。
  • 单因素分析显示,CAPA患者较非CAPA患者更常见免疫抑制,ICU期间更常需要IMV、血管升压药和肾脏替代治疗。
  • 多因素logistic回归分析中,ICU入科时SAPS II评分、免疫抑制和SARS-CoV-2 Delta变异株与CAPA独立相关。
  • CAPA与28天死亡率无显著关联,但CAPA患者机械通气时间和ICU住院时间更长。

证据类型、等级与局限

  • 证据类型:前瞻性多中心观察性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在Delta与Omicron变异株时代,重症COVID-19患者CAPA患病率低于早期报道,主要影响接受有创机械通气的患者。
  • CAPA患者机械通气时间和ICU住院时间显著更长,提示临床需关注此类患者的ICU资源占用。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: During the first COVID-19 pandemic wave, COVID-19-associated pulmonary aspergillosis (CAPA) has been reported in up to 11-28% of critically ill COVID-19 patients and associated with increased mortality. As new SARS-CoV-2 variants emerged, the characteristics of critically ill COVID-19 patients have evolved, particularly in the era of Omicron. The purpose of this study is to investigate the characteristics of CAPA in the era of new variants.

METHODS: This is a prospective multicenter observational cohort study conducted in France in 36 participating intensive care units (ICU), between December 7th, 2021 and April 26th 2023. Diagnosis criteria of CAPA relied on European Confederation of Medical Mycology (ECMM)/International Society for Human & Animal Mycology (ISHAM) consensus criteria.

RESULTS: 566 patients were included over the study period. The prevalence of CAPA was 5.1% [95% CI 3.4-7.3], and rose to 9.1% among patients who required invasive mechanical ventilation (IMV). Univariable analysis showed that CAPA patients were more frequently immunosuppressed and required more frequently IMV support, vasopressors and renal replacement therapy during ICU stay than non-CAPA patients. SAPS II score at ICU admission, immunosuppression, and a SARS-CoV-2 Delta variant were independently associated with CAPA in multivariable logistic regression analysis. Although CAPA was not significantly associated with day-28 mortality, patients with CAPA experienced a longer duration of mechanical ventilation and ICU stay.

CONCLUSION: This study contributes valuable insights into the prevalence, characteristics, and outcomes of CAPA in the era of Delta and Omicron variants. We report a lower prevalence of CAPA (5.1%) among critically-ill COVID-19 patients than previously reported, mainly affecting intubated-patients. Duration of mechanical ventilation and ICU stay were significantly longer in CAPA patients.

来源:Ann Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Bay P, Audureau E, Préau S, et al. COVID-19 associated pulmonary aspergillosis in critically-ill patients: a prospective multicenter study in the era of Delta and Omicron variants. Ann Intensive Care. 2024. PMID: 38658426. doi:10.1186/s13613-024-01296-0

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。